Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu(R) for Knee Osteoarthritis Pain
(NASDAQ:ORGO), Clinical Development Program Appropriate for Rolling BLA Submission Expected by the End of 2025 CANTON, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) — Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today […]